The Indian pharmaceutical manufacturer Ranbaxy yesterday launched its generic version of abacavir, trade named Virol. The drug will cost around 6,500 rupees a month (£85/$142).
Ranbaxy says that Virol is bioequivalent to Glaxo Smith Kline’s Ziagen, the originator brand, although World Health Organisation review has not yet been carried out. Three Ranbaxy products – zidovudine, nevirapine and zidovudine/lamivudine combination tablets – have already been approved as bioequivalent by WHO and appear on its pre-qualified antiretrovirals list.
Initially Virol will only be available in India, but Ranbaxy will be keen to see Virol adopted as the preferred form of abacavir used by antiretroviral access programmes in resource-limited countries. Abacavir is recommended as a preferred element of first-line therapy due to its ease of dosing (one 300mg tablet twice daily, no food restrictions), and because of its lack of interaction with anti-TB medications.
However, Virol is likely to be considered less convenient than Trizivir, Glaxo Smith Kline’s coformulation of zidovudine, lamivudine and abacavir, which can be dosed as one tablet twice a day. GSK is currently offering Trizivir at a price of $1624 a year to least developed countries and all African states, as well as all projects fully financed by the Global Fund to Fight AIDS. TB and Malaria. GSK’s Ziagen is offered on the same basis at $986 a year.
In comparison Virol would cost $1704 a year if it were offered to least-developed countries at the domestic price.
Further information
Further information on this website
Issues to consider in the choice of regimens in resource-limited settings